Jonathan Weiss / Shutterstock.com
Goldfinch Bio, a US company focused on developing treatments for kidney disease, has agreed to license a cannabinoid receptor 1 (CB1) antibody from Japanese pharmaceutical manufacturer Takeda.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Goldfinch Bio, cannabinoid, receptor, CB1, kidney disease, Takeda, licence, antibody
